MarketCap
Facebook
X
Telegram
Landos Biopharma Market Cap | LABP
As of October 17, 2026 Landos Biopharma has a market cap of $ 144 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Landos Biopharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.1 M | 1.05 M | 129 M | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 129 M | 1.05 M | 59.3 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Outlook Therapeutics
OTLK
|
61.6 M | $ 0.49 | 0.04 % | $ 17.1 M |  USA |
 |
Protagonist Therapeutics
PTGX
|
5.53 B | $ 128.75 | 0.2 % | $ 8.19 B | USA |
 |
Passage Bio
PASG
|
18.8 M | $ 3.5 | 4.44 % | $ 11.2 M | USA |
 |
Forte Biosciences
FBRX
|
335 M | $ 76.99 | 0.03 % | $ 997 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
5.45 B | $ 80.14 | 3.04 % | $ 4.02 B | USA |
 |
Inhibikase Therapeutics
IKT
|
160 M | $ 1.65 | 1.67 % | $ 162 M | USA |
|
Immatics N.V.
IMTX
|
735 M | $ 6.73 | 2.0 % | $ 823 M |  Germany |
 |
Immunic
IMUX
|
145 M | $ 6.97 | 0.56 % | $ 1.09 B | USA |
 |
Immunovant
IMVT
|
6.49 B | $ 26.73 | 0.57 % | $ 4.88 B | USA |
 |
MediciNova
MNOV
|
69.2 M | $ 1.42 | 0.69 % | $ 69.7 M | USA |
 |
Iovance Biotherapeutics
IOVA
|
1.35 M | $ 13.62 | 3.59 % | $ 4.87 M | USA |
|
Rezolute
RZLT
|
409 M | $ 3.58 | 0.12 % | $ 372 M | USA |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Krystal Biotech
KRYS
|
8.46 B | $ 316.58 | 0.82 % | $ 9.16 B | USA |
 |
Nektar Therapeutics
NKTR
|
1.09 B | $ 35.78 | 2.25 % | $ 604 M | USA |
 |
NanoViricides
NNVC
|
30.3 M | $ 1.38 | 0.73 % | $ 27.9 M | USA |
 |
Grifols, S.A.
GRFS
|
4.52 B | $ 7.64 | 1.33 % | $ 5.19 B |  Spain |
 |
Nurix Therapeutics
NRIX
|
1.57 B | $ 24.42 | 0.12 % | $ 2.12 B | USA |
 |
Ocugen
OCGN
|
615 M | $ 0.78 | 0.06 % | $ 244 M | USA |
 |
Oragenics
OGEN
|
1.73 M | $ 0.43 | 1.69 % | $ 928 K | USA |
 |
Omeros Corporation
OMER
|
671 M | $ 16.2 | 1.95 % | $ 1.03 B | USA |
 |
ORIC Pharmaceuticals
ORIC
|
1.02 B | $ 12.35 | 10.18 % | $ 1.08 B | USA |
 |
Aligos Therapeutics
ALGS
|
65.9 M | $ 4.86 | 3.06 % | $ 48 M | USA |
 |
Alkermes plc
ALKS
|
5.13 B | $ 41.22 | 2.79 % | $ 6.79 B |  Irlanda |
 |
Jazz Pharmaceuticals plc
JAZZ
|
10.5 B | $ 210.23 | 2.28 % | $ 12.8 B | Irlanda |
 |
Phio Pharmaceuticals Corp.
PHIO
|
7.06 M | $ 0.87 | 0.05 % | $ 5.21 M | USA |
 |
Kymera Therapeutics
KYMR
|
7.93 B | $ 104.78 | 1.23 % | $ 8.85 B | USA |
 |
Praxis Precision Medicines
PRAX
|
7.31 B | $ 241.76 | 3.86 % | $ 5.44 B | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
162 M | $ 1.31 | 0.34 % | $ 138 M |  Niderland |
 |
PTC Therapeutics
PTCT
|
5.56 B | $ 59.24 | 2.21 % | $ 4.71 B | USA |
 |
Arcus Biosciences
RCUS
|
2.17 B | $ 22.12 | 1.26 % | $ 2.38 B | USA |
|
Larimar Therapeutics
LRMR
|
371 M | $ 1.99 | 1.51 % | $ 165 M | USA |
 |
Regeneron Pharmaceuticals
REGN
|
81.3 B | $ 790.74 | 0.01 % | $ 82.7 B | USA |
 |
Rafael Holdings
RFL
|
39.4 M | $ 1.39 | 2.8 % | $ 40.9 M | USA |
 |
REGENXBIO
RGNX
|
444 M | $ 6.93 | 4.07 % | $ 357 M | USA |
 |
Royalty Pharma plc
RPRX
|
18.9 B | $ 60.96 | 2.25 % | $ 26.2 B | USA |
 |
Seer
SEER
|
123 M | $ 2.03 | 0.44 % | $ 112 M | USA |
 |
PDS Biotechnology Corporation
PDSB
|
25 M | $ 1.13 | 0.62 % | $ 52.4 M | USA |
 |
SIGA Technologies
SIGA
|
404 M | $ 3.17 | 0.16 % | $ 227 M | USA |
 |
Nanobiotix S.A.
NBTX
|
1.45 T | $ 21.3 | 4.46 % | $ 1.02 T |  France |
 |
Syndax Pharmaceuticals
SNDX
|
1.73 B | $ 12.9 | 0.89 % | $ 1.12 B | USA |
 |
Soligenix
SNGX
|
6.12 M | $ 0.35 | 1.67 % | $ 1.82 M | USA |
 |
Intellia Therapeutics
NTLA
|
776 M | $ 11.42 | 0.71 % | $ 1.24 B | USA |
|
Nuvation Bio
NUVB
|
1.99 B | $ 4.45 | 1.6 % | $ 1.52 B | USA |
 |
Sarepta Therapeutics
SRPT
|
1.64 B | $ 17.1 | 0.03 % | $ 1.71 B | USA |
 |
Processa Pharmaceuticals
PCSA
|
4.14 M | $ 1.69 | 0.6 % | $ 2.21 M | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
24 B | $ 0.48 | 0.2 % | $ 5.91 B |  Israel |
 |
SELLAS Life Sciences Group
SLS
|
567 M | $ 9.98 | 4.02 % | $ 1.09 B | USA |
|
Protara Therapeutics
TARA
|
245 M | $ 2.32 | 1.46 % | $ 99.4 M | USA |
 |
Relay Therapeutics
RLAY
|
546 M | $ 16.28 | 1.41 % | $ 2.79 B | USA |